Susquehanna International Group, LLP Ngm Biopharmaceuticals Inc Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $29,148 - $63,639	-48,580 Reduced 58.06%	35,092 $30,000
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $26,072 - $83,680	24,831 Added 42.2%	83,672 $89,000
Q2 2023 Aug 11, 2023	SELL	$2.44 - $4.53 $18,500 - $34,346	-7,582 Reduced 11.41%	58,841 $152,000
Q1 2023 May 16, 2023	BUY	$3.72 - $5.4 $247,093 - $358,684	66,423 New	66,423 $271,000
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $10,714 - $15,037	-851 Reduced 6.74%	11,768 $154,000
Q2 2022 Aug 15, 2022	SELL	$10.58 - $17.5 $15,108 - $24,990	-1,428 Reduced 10.17%	12,619 $162,000
Q2 2021 Aug 11, 2021	BUY	$15.06 - $30.03 $4,954 - $9,879	329 Added 2.4%	14,047 $277,000
Q4 2020 Feb 16, 2021	BUY	$16.21 - $31.44 $38,806 - $75,267	2,394 Added 21.14%	13,718 $416,000
Q3 2020 Nov 16, 2020	SELL	$15.59 - $19.97 $12,612 - $16,155	-809 Reduced 6.67%	11,324 $180,000
Q2 2020 Aug 14, 2020	BUY	$11.97 - $23.47 $8,450 - $16,569	706 Added 6.18%	12,133 $240,000
Q1 2020 May 15, 2020	BUY	$10.0 - $19.51 $114,270 - $222,940	11,427 New	11,427 $141,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.